We are live on ! Find out more
ACA

Avoro Capital Advisors Portfolio holdings

AUM $10.2B
1-Year Est. Return 149.19%
This Fund
S&P 500
This Quarter Est. Return
-7.42%
1 Year Est. Return
+149.19%
3 Year Est. Return
+425.03%
5 Year Est. Return
+775.33%
10 Year Est. Return
+45,729.2%
AUM
$495M
AUM Growth
-$74.9M
Cap. Flow
+$18.8M
Cap. Flow %
3.8%
Top 10 Hldgs %
58.78%
Holding
54
New
6
Increased
19
Reduced
13
Closed
11

Top Buys

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$20.8M
2
ACAD icon
Acadia Pharmaceuticals
ACAD
+$18.4M
3
ASND icon
Ascendis Pharma A/S
ASND
+$9.99M
4
SGEN
Seagen Inc. Common Stock
SGEN
+$9.26M
5
NDRM
NeuroDerm Ltd. Ordinary Shares
NDRM
+$6.92M

Top Sells

Rank Stock Value
1
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$17.7M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$14.4M
3
AGIO icon
Agios Pharmaceuticals
AGIO
+$7.92M
4
VNDA icon
Vanda Pharmaceuticals
VNDA
+$7.17M
5
BMY icon
Bristol-Myers Squibb
BMY
+$6.28M

Sector Composition

Rank Sector Weight
1 Healthcare 81.51%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CASC
26
DELISTED
Cascadian Therapeutics, Inc.
CASC
$3.97M 0.8%
921,248
-13,973
-1% -$90.3K
XNCR icon
27
Xencor
XNCR
$1.5B
$3.29M 0.66%
+125,000
New +$3.01M
ASMB icon
28
Assembly Biosciences
ASMB
$498M
$3.28M 0.66%
22,524
+181
+0.8% +$26.9K
FBIO icon
29
Fortress Biotech
FBIO
$104M
$3.24M 0.65%
80,023
-10,419
-12% -$389K
CRVS icon
30
Corvus Pharmaceuticals
CRVS
$1.12B
$3.1M 0.63%
216,619
-51,750
-19% -$787K
OTLK icon
31
Outlook Therapeutics
OTLK
$183M
$2.06M 0.42%
4,272
+1,454
+52% +$814K
CLLS
32
Cellectis
CLLS
$277M
$1.65M 0.33%
97,096
+38,425
+65% +$710K
ARRY
33
DELISTED
Array Biopharma Inc
ARRY
$1.41M 0.28%
+160,000
New +$1.18M
TRIL
34
DELISTED
Trillium Therapeutics Inc.
TRIL
$1.28M 0.26%
227,399
-88,621
-28% -$882K
CPRX
35
DELISTED
Catalyst Pharmaceutical
CPRX
$1.2M 0.24%
+1,141,149
New +$1.3M
BDSI
36
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$1.13M 0.23%
+644,176
New +$1.32M
SRPT icon
37
PUT
Sarepta Therapeutics
SRPT
$1.57B
$615K 0.12%
150,000
+74,400
+98% +$2.99M
ACAD icon
38
CALL
Acadia Pharmaceuticals
ACAD
$4.43B
$413K 0.08%
+200,000
New +$5.29M
ONSIZ
39
DELISTED
Oncobiologics, Inc. Series B Warrant
ONSIZ
$184K 0.04%
233,333
– –
ONSIW
40
DELISTED
Oncobiologics, Inc. Series A Warrant Expiring 2/18/2019
ONSIW
$44K 0.01%
233,333
– –
AGEN
41
CALL
Agenus
AGEN
$312M
$25K 0.01%
50,950
– –
IMMU
42
CALL
DELISTED
Immunomedics Inc
IMMU
$23K ﹤0.01%
300,800
– –
AGIO icon
43
Agios Pharmaceuticals
AGIO
$1.79B
– –
-150,000
Closed -$7.92M
IBRX icon
44
ImmunityBio
IBRX
$7.51B
– –
-72,412
Closed -$563K
SRPT icon
45
CALL
Sarepta Therapeutics
SRPT
$1.57B
– –
-190,000
Closed -$6.03M
VCEL icon
46
Vericel Corp
VCEL
$2.35B
– –
-215,744
Closed -$604K
KA
47
DELISTED
Kineta, Inc. Common Stock
KA
– –
-1,283
Closed -$2.8M
ARAV
48
DELISTED
Aravive, Inc. Common Stock
ARAV
– –
-15,957
Closed -$1.17M
DRNA
49
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
– –
-46,082
Closed -$271K
GWPH
50
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
– –
-133,600
Closed -$17.7M
1
2
3

Similar funds

IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
OIA
OneDigital Investment Advisors Overland Park, Kansas $10.2B AUM 16.58% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

Avoro Capital Advisors's Q4 2016 Portfolio in Review

As of Q4 2016, Avoro Capital Advisors held 54 positions worth $495M, down 13% from $570M the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Avoro Capital Advisors deployed $18.8M of net new capital in Q4 2016, opening 6 new positions and adding to 19 existing holdings. Its largest new stake was Alexion Pharmaceuticals: 170,000 shares worth $20.8M.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, down from 83% a quarter earlier.

On the sell side, the largest reduction was Sarepta Therapeutics, an estimated $14.4M trimmed.

  • Avoro Capital Advisors's largest Q4 2016 buy was Alexion Pharmaceuticals: 170,000 shares worth $20.8M.
  • Avoro Capital Advisors added most to Acadia Pharmaceuticals in Q4 2016, an estimated $18.4M increase.
  • Avoro Capital Advisors's biggest Q4 2016 reduction was Sarepta Therapeutics, cutting an estimated $14.4M.
  • Avoro Capital Advisors fully exited GW Pharmaceuticals Plc American Depositary Shares in Q4 2016, selling an estimated $17.7M.
  • Avoro Capital Advisors's ten largest holdings make up 59% of its $495M portfolio in Q4 2016.
  • Avoro Capital Advisors opened 6 new positions and closed 11 in Q4 2016.
  • Avoro Capital Advisors's portfolio value fell 13% quarter-over-quarter to $495M.

Based on Avoro Capital Advisors's 13F filing for Q4 2016, filed 14 Feb 2017.